Stryker Corporation $SYK Shares Bought by Venture Visionary Partners LLC

Key Points

• Venture Visionary Partners LLC increased its stake in Stryker Corporation by 21.7%, owning 5,199 shares valued at approximately $2,057,000 as of its latest SEC filing.
• Institutional investors hold 77.09% of Stryker's stock, with significant transactions including Nuveen LLC's new stake worth about $558 million and AllianceBernstein L.P.'s stake growing by 66.7%.
• Stryker announced a quarterly dividend of $0.84 per share, with an annualized yield of 0.9%, expected to be paid on October 31st.

Venture Visionary Partners LLC raised its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 21.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,199 shares of the medical technology company's stock after acquiring an additional 926 shares during the period. Venture Visionary Partners LLC's holdings in Stryker were worth $2,057,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Nuveen LLC acquired a new stake in Stryker in the 1st quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD boosted its position in shares of Stryker by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company's stock worth $4,515,847,000 after buying an additional 1,021,496 shares during the period. Alliancebernstein L.P. grew its stake in shares of Stryker by 66.7% in the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company's stock valued at $511,152,000 after buying an additional 549,643 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Stryker by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company's stock valued at $12,306,572,000 after buying an additional 361,136 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company's stock worth $838,640,000 after acquiring an additional 261,058 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on SYK shares. Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. BTIG Research restated a "buy" rating on shares of Stryker in a report on Monday, July 14th. Truist Financial set a $415.00 target price on shares of Stryker and gave the stock a "hold" rating in a research note on Monday, August 4th. Evercore ISI raised their price target on shares of Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Finally, Wall Street Zen downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research note on Friday, September 26th. Fourteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $430.33.

Insiders Place Their Bets

In related news, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company's stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.20% of the company's stock.

Stryker Stock Down 0.1%

Shares of NYSE SYK opened at $369.44 on Wednesday. The business has a 50-day moving average of $384.81 and a two-hundred day moving average of $379.11. The company has a market capitalization of $141.24 billion, a price-to-earnings ratio of 48.93, a price-to-earnings-growth ratio of 2.67 and a beta of 0.93. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business's revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's dividend payout ratio is presently 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.